Beneficial effects of combined terlipressin and tetramethylpyrazine administration on portal hypertensive rats

Canadian Journal of Physiology and Pharmacology

Volumn 77, Issue 8, 1999, Pages 618-624

  Chang, Fang Chi ^a   Huang, Yi Tsau ^b   Lin, Han Chieh ^b   Hong, Chuang Ye ^b   Lin, Jaung Geng ^c   Chen, Ke Ji ^a  

^a XIYUAN HOSPITAL   (China)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; Hemodynamics; Portal hypertension; Terlipressin; Tetramethylpyrazine

Indexed keywords

TERLIPRESSIN; TETRAMETHYLPYRAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

EID: 0032720863     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y99-064     Document Type: Article

References (38)

1. Beijing Research Institute of the Pharmaceutical Industry. 1977a. Research on the active ingredients of Ligusticum wallichii. I. Extraction, separation, and chemical characterization. Chin. Med. J. 7: 420-421.
2. Beijing Research Institute of the Pharmaceutical Industry. 1977b. Research on the active ingredients of Ligusticum wallichii.. III. Clinical (218 cases) use of tetramethylpyrazine in the treatment of hypoxemic cerebral vascular diseases. Chin. Med. J. 7: 467-469.
3. Blei, A.T., Groszmann, R.J., Gusberg, R., and Conn, H.O. 1980. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig. Dis. Sci. 25: 688-694.
4. Chang, F.-C., Chen, K.-J., Lin, J.-G., Hong, C.-Y., and Huang, Y.-T. 1998. Effects of tetramethylpyrazine on portal hypertensive rats. J. Pharm. Pharmacol. 50: 881-884.
5. Chojkier, M., and Groszmann, R.J. 1981. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am. J. Physiol. 240: G371-G375.
6. D'Amico, G., Pagliaro, L., and Bosch, J. 1995. The treatment of portal hypertension: a meta-analytic review. Hepatology. 22: 332-354.
7. Genecin, P., and Groszmann, R.J. 1994. The biology of portal hypertension. In The liver: biology and pathobiology. 3rd ed. Edited by I.M. Arias, J.L. Boyer, N. Fausto, W.B. Jakoby, D.A. Schachter, and D.A. Shafritz. Raven Press, New York. pp. 1327-1341.
8. Gimson, A.E.S., Westaby, D., Hayes, P.C., Hegarty, J., Watson, A., and Williams, R. 1986. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology, 6: 410-413.
9. Groszmann, R.J., Kravetz, D., Bosch, J., Glickman, M., Bruix, J., Bredfeldt, J.E., Conn, H.O., Rodes, J., and Storer, E.H. 1982. Nitroglycerin improves the hemodynamic responses to vasopressin in portal hypertension. Hepatology, 2: 757-762.
10. Hadengue, A., Moreau, R., Cerini, R. Koshy, A., Lee, S.S., and Lebrec, D. 1989. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology, 9: 83-87.
11. Hori, N., Okanoue, T., Sawa, Y., Itoh, Y., Mori, T., Takami, S., and Kashima, K. 1994. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose iso-sorbide dinitrate on portal hypertension in conscious cirrhotic rats. J. Gastroenterol. 29: 460-468.
12. Huang, Y.-T., Wang, G.-F., Yang, M.C.M., Chang, S.-P., Lin, H.-C. and Hong, C.-Y. 1996. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J. Pharmacol. Exp. Ther. 278: 535-541.
13. Huang, Y.-T., Lin, H.-C., Tsai, J.-F., Hou, M.-C., and Hong, C.-Y. 1997a. Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats. Eur. J. Clin. Invest. 27: 550-555.
14. Huang, Y.-T., Tsai, J.-F., Lin, H.-C., Chen, C.-F., and Hong, C.-Y. 1997b. Hemodynamic effects of acute tetrandrine and terlipressin administration on portal hypertensive rats. Can. J. Physiol. Pharmacol. 75: 1220-1225. (Erratum: Can. J. Physiol. Pharmacol. 76: 467. 1998.)
15. Huang, Y.-T., Cheng, Y.-R., Lin, H.-C., Hou, M.-C., Lee, S.-D., and Hong, C.-Y. 1998. Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats. Dig. Dis. Sci. 43: 358-364.
16. Kosuqe, T., and Kamiya, H. 1962. Discovery of a pyrazine in a natural product: tetramethylpyrazine from culture of a strain of Bacillus subtilis. Nature (London), 193: 776.
17. Kountouras, J., Billing, B.H., and Scheuer, P.J. 1984. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 65: 305-311.
18. Kroeger, R.J., and Groszmann, R.J. 1985. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology, 5: 425-430.
19. Lebrec, D. 1994. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol. Ther. 61: 65-107.
20. Lee, F.-Y., Tsai, Y.-T., Lin, H.-C, Lee, S.-D., Hsia, H.-C., Lin, W.-J., Wang, S.-S., Lai, K.-H., and Lo, K.-J. 1992. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J. Hepatol. 15: 54-58.
21. Lee, S.S., Girod, C., Braillon, A., Hadengue, A., and Lebrec, D. 1986. Hemodynamic characterization of chronic bile ductligated rats: effect of pentobarbital sodium. Am. J. Physiol. 251: G176-G180.
22. Ludbrook, J. 1994. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28: 303-311.
23. Moreau, R., Cailmail, S., and Lebrec, D. 1994. Effects of vasopressin on haemodynamics in portal hypertensive rats receiving clonidine. Liver, 14: 45-49.
24. Oberti, F., Rifflet, H., Maiga, M.Y., Pilette, C., Gallois, Y., Douay, O., Le Jeune, J.-J., Saumet, J.-L., and Cales, P. 1997. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J. Hepatol. 26: 167-173.
25. Oberti, F., Veal, N., Kaassis, M., Pilette, C., Rifflet, H., Trouve, R., and Cales, P. 1998. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J. Hepatol. 29: 103-111.
26. Ojewole, J.A.O., and Odibiyi, O.O. 1980. Neuromuscular and cardiovascular actions of tetramethylpyrazine from the stem of Jatropha podagrica. Planta Med. 38: 332-338.
27. Pang, P.K.T., Shan, J.J., and Chiu, K.W. 1996. Tetramethylpyrazine, a calcium antagonist. Planta Med. 62: 431-435.
28. Peng, W., and Duan, S.F. 1992. Effects of ligustrazine controlled release capsule on pulmonary hemodynamics in chronic pulmonary heart disease. Chin. J. Tuberc. Respir. Dis. 15: 217-219.
29. Peng, W., Hucks, D., Priest, R.M., Kan, Y.M., and Ward, J.P.T. 1996. Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism. Br. J. Pharmacol. 119: 1063-1071.
30. Roulot, D., Gaudin, C., Braillon, A., Sekiyama, T., Bacq, Y., and Lebrec, D. 1989. Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. Can. J. Physiol. Pharmacol. 67: 1369-1372.
31. Sikuler, E., Kravetz, D., and Groszmann, R.J. 1985. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 248: G618-G625.
32. Sogni, P., Soupison, T., Moreau, R., Le Moine, O., Bacq, Y., Hadengue, A., and Lebrec, D. 1994. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving β-adrenergic antagonists. J. Hepatol. 20: 548-552.
33. Tsai, Y.-T., Lay, C.-S., Lai, K.-H., Ng, W.-W., Yeh, Y.-S., Wang, J.-Y., Chiang, T.-T., Lee, S.-D., and Chiang, B.N. 1986. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology, 6: 406-409.
34. Vachiery, F., Moreau, R., Gadano, A., Yang, S., Sogni, P., Hadengue, A., Cailmail, S., Soupison, T., and Lebrec, D. 1996. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective β-blocker. Dig. Dis. Sci. 41: 1722-1726.
35. van de Casteele, M., Roey, G.V., Nevens, F., and Fevery, J. 1996. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology, 24: 1492-1496.
36. Walker, S. 1990. Vasoconstrictor therapy in bleeding esophageal varices. Hepato-gastroenterology, 37: 538-543.
37. Wang, Z.L., Kwan, C.Y., Ohta, A., and Chen, M.C. 1991. Inhibitory effects of tetramethyl and tetraethyl derivatives of pyrazine on dog saphenous vein. Can. J. Physiol. Pharmacol. 69: 1184-1189.
38. Wu, C.-C., Chiou, W.-F., and Yen, M.-H. 1989. A possible mechanism of action of tetramethylpyrazine on vascular smooth muscle in rat aorta. Eur. J. Pharmacol. 169: 189-195.